Primary medical (neo-adjuvant) chemotherapy for operable breast cancer
Ian E. Smith, Alison Jones, Mary E.R. O'Brien et al. · European Journal of Cancer · 1993
Cited by 100 works. doi:10.1016/0959-8049(93)90133-z
Authors
References
- Assessment of response to therapy in advanced breast cancer
- Primary Chemotherapy To Avoid Mastectomy in Tumors With Diameters of Three Centimeters or More
- Assessment of response to therapy in advanced breast cancer
- Presence of a growth-stimulating factor in serum following primary tumor removal in mice.
- Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth-stimulating factor in mice.
- Locally advanced breast cancer: The contribution of cytotoxic and endocrine treatment to radiotherapy
- Primary systemic therapy for operable breast cancer
- A Personal Experience with Halstedʼs Radical Mastectomy
- A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer